XOMAP
XOMA Corporation
Biotechnology
Market Cap$306M
5Y Perf.+1.4%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
XOMAP vs PRTC vs ABBV vs PFE
Revenue, margins, valuation, and 5-year total return — side by side.
PRTC
PureTech Health plc
Biotechnology
Market Cap$41M
5Y Perf.-68.6%
ABBV
AbbVie Inc.
Drug Manufacturers - General
Market Cap$358.42B
5Y Perf.+89.1%
PFE
Pfizer Inc.
Drug Manufacturers - General
Market Cap$150.63B
5Y Perf.-28.1%
XOMAP vs PRTC vs ABBV vs PFE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | XOMAP | PRTC | ABBV | PFE |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Drug Manufacturers - General | Drug Manufacturers - General |
| Market Cap | $306M | $41M | $358.42B | $150.63B |
| Revenue (TTM) | $52M | $9M | $61.16B | $63.31B |
| Net Income (TTM) | $32M | $-56M | $4.23B | $7.49B |
| Gross Margin | 94.3% | -196.2% | 70.2% | 69.3% |
| Operating Margin | 21.8% | -26.2% | 26.7% | 23.4% |
| Forward P/E | 22.5x | — | 14.3x | 8.9x |
| Total Debt | $132M | $20M | $69.07B | $67.42B |
| Cash & Equiv. | $83M | $254M | $5.23B | $1.14B |
XOMAP vs PRTC vs ABBV vs PFE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
XOMAP
PRTC
ABBV
PFE
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| XOMA Corporation (XOMAP) | 100 | 101.4 | +1.4% |
| PureTech Health plc (PRTC) | 100 | 31.4 | -68.6% |
| AbbVie Inc. (ABBV) | 100 | 189.1 | +89.1% |
| Pfizer Inc. (PFE) | 100 | 71.9 | -28.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XOMAP vs PRTC vs ABBV vs PFE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: XOMAP leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Pfizer Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
XOMAP
XOMA Corporation
The Growth Play
XOMAP carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 83.1%, EPS growth 188.5%, 3Y rev CAGR 105.3%
- Lower volatility, beta 0.03, current ratio 3.37x
- Beta 0.03, yield 1.2%, current ratio 3.37x
- 83.1% revenue growth vs PRTC's -3.5%
Best for: growth exposure and sleep-well-at-night
PRTC
PureTech Health plc
The Lower-Volatility Pick
PRTC plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
ABBV
AbbVie Inc.
The Long-Run Compounder
ABBV is the clearest fit if your priority is long-term compounding.
- 295.5% 10Y total return vs XOMAP's 50.9%
Best for: long-term compounding
PFE
Pfizer Inc.
The Income Pick
PFE is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 15 yrs, beta 0.54, yield 6.5%
- Lower P/E (8.9x vs 14.3x)
- 6.5% yield, 15-year raise streak, vs ABBV's 3.2%, (1 stock pays no dividend)
- +23.7% vs PRTC's -2.6%
Best for: income & stability
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | XOMAP | 83.1% revenue growth vs PRTC's -3.5% |
| Value | PFE | Lower P/E (8.9x vs 14.3x) |
| Quality / Margins | XOMAP | 60.8% margin vs PRTC's -6.2% |
| Stability / Safety | XOMAP | Beta 0.03 vs PFE's 0.54 |
| Dividends | PFE | 6.5% yield, 15-year raise streak, vs ABBV's 3.2%, (1 stock pays no dividend) |
| Momentum (1Y) | PFE | +23.7% vs PRTC's -2.6% |
| Efficiency (ROA) | XOMAP | 13.0% ROA vs PRTC's -9.9%, ROIC 6.8% vs -66.9% |
XOMAP vs PRTC vs ABBV vs PFE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
FY 2025
XOMAP vs PRTC vs ABBV vs PFE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPFELAGGINGPRTC
Who Leads Where
PFE leads in 2 of 6 categories
ABBV leads 1 • XOMAP leads 0 • PRTC leads 0 • 3 tied
Explore the data ↓PRTCPureTech Health plc
0leads
XOMAPXOMA Corporation
0leads
ABBVAbbVie Inc.
1leads
PFEPfizer Inc.
2leads
6 Total Categories
CATEGORYLEADERvs ABBVvs XOMAPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
PFE4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
ABBV4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
PFE2/2
Income & Cash Flow (Last 12 Months)
Evenly matched — XOMAP and ABBV each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PFE is the larger business by revenue, generating $63.3B annually — 7063.7x PRTC's $9M. XOMAP is the more profitable business, keeping 60.8% of every revenue dollar as net income compared to PRTC's -6.2%. On growth, XOMAP holds the edge at +57.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | XOMAPXOMA Corporation | PRTCPureTech Health p… | ABBVAbbVie Inc. | PFEPfizer Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $52M | $9M | $61.2B | $63.3B |
| EBITDAEarnings before interest/tax | $14M | -$228M | $24.5B | $21.0B |
| Net IncomeAfter-tax profit | $32M | -$56M | $4.2B | $7.5B |
| Free Cash FlowCash after capex | $3M | -$219M | $18.7B | $9.5B |
| Gross MarginGross profit ÷ Revenue | +94.3% | -196.2% | +70.2% | +69.3% |
| Operating MarginEBIT ÷ Revenue | +21.8% | -26.2% | +26.7% | +23.4% |
| Net MarginNet income ÷ Revenue | +60.8% | -6.2% | +6.9% | +11.8% |
| FCF MarginFCF ÷ Revenue | +5.4% | -24.4% | +30.6% | +15.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +57.9% | -30.5% | +10.0% | +5.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -68.3% | -8.7% | +57.4% | -9.5% |
Evenly matched — XOMAP and ABBV each lead in 3 of 6 comparable metrics.
Valuation Metrics
PFE leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 17.3x trailing earnings, XOMAP trades at a 80% valuation discount to ABBV's 85.5x P/E. On an enterprise value basis, PFE's 10.7x EV/EBITDA is more attractive than XOMAP's 24.7x.
| Metric | XOMAPXOMA Corporation | PRTCPureTech Health p… | ABBVAbbVie Inc. | PFEPfizer Inc. |
|---|---|---|---|---|
| Market CapShares × price | $306M | $41M | $358.4B | $150.6B |
| Enterprise ValueMkt cap + debt − cash | $355M | -$193M | $422.3B | $216.9B |
| Trailing P/EPrice ÷ TTM EPS | 17.35x | -0.37x | 85.50x | 19.47x |
| Forward P/EPrice ÷ next-FY EPS est. | 22.54x | — | 14.28x | 8.94x |
| PEG RatioP/E ÷ EPS growth rate | 1.30x | — | — | — |
| EV / EBITDAEnterprise value multiple | 24.70x | — | 14.96x | 10.66x |
| Price / SalesMarket cap ÷ Revenue | 5.87x | 8.79x | 5.86x | 2.41x |
| Price / BookPrice ÷ Book value/share | 4.38x | 0.13x | — | 1.74x |
| Price / FCFMarket cap ÷ FCF | 106.58x | — | 20.12x | 16.60x |
PFE leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
Evenly matched — PRTC and ABBV each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
ABBV delivers a 62.1% return on equity — every $100 of shareholder capital generates $62 in annual profit, vs $-16 for PRTC. PRTC carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to XOMAP's 1.27x. On the Piotroski fundamental quality scale (0–9), PFE scores 7/9 vs PRTC's 5/9, reflecting strong financial health.
| Metric | XOMAPXOMA Corporation | PRTCPureTech Health p… | ABBVAbbVie Inc. | PFEPfizer Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +32.6% | -16.1% | +62.1% | +8.3% |
| ROA (TTM)Return on assets | +13.0% | -9.9% | +3.1% | +3.6% |
| ROICReturn on invested capital | +6.8% | -66.9% | +23.9% | +7.5% |
| ROCEReturn on capital employed | +5.2% | -18.8% | +21.5% | +9.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 6 | 7 |
| Debt / EquityFinancial leverage | 1.27x | 0.06x | — | 0.78x |
| Net DebtTotal debt minus cash | $49M | -$234M | $63.8B | $66.3B |
| Cash & Equiv.Liquid assets | $83M | $254M | $5.2B | $1.1B |
| Total DebtShort + long-term debt | $132M | $20M | $69.1B | $67.4B |
| Interest CoverageEBIT ÷ Interest expense | 1.47x | -1.16x | 3.28x | 4.02x |
Evenly matched — PRTC and ABBV each lead in 3 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ABBV leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ABBV five years ago would be worth $20,131 today (with dividends reinvested), compared to $2,988 for PRTC. Over the past 12 months, PFE leads with a +23.7% total return vs PRTC's -2.6%. The 3-year compound annual growth rate (CAGR) favors ABBV at 14.6% vs PRTC's -16.3% — a key indicator of consistent wealth creation.
| Metric | XOMAPXOMA Corporation | PRTCPureTech Health p… | ABBVAbbVie Inc. | PFEPfizer Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -2.6% | +2.0% | -10.1% | +6.9% |
| 1-Year ReturnPast 12 months | +6.9% | -2.6% | +11.3% | +23.7% |
| 3-Year ReturnCumulative with dividends | +31.2% | -41.3% | +50.4% | -18.4% |
| 5-Year ReturnCumulative with dividends | +42.5% | -70.1% | +101.3% | -13.3% |
| 10-Year ReturnCumulative with dividends | +50.9% | -55.9% | +295.5% | +29.6% |
| CAGR (3Y)Annualised 3-year return | +9.5% | -16.3% | +14.6% | -6.6% |
ABBV leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — XOMAP and PFE each lead in 1 of 2 comparable metrics.
Risk & Volatility
XOMAP is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than PFE's 0.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PFE currently trades 92.1% from its 52-week high vs ABBV's 82.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XOMAPXOMA Corporation | PRTCPureTech Health p… | ABBVAbbVie Inc. | PFEPfizer Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.03x | 0.51x | 0.34x | 0.54x |
| 52-Week HighHighest price in past year | $30.00 | $19.92 | $244.81 | $28.75 |
| 52-Week LowLowest price in past year | $25.14 | $14.50 | $176.57 | $21.97 |
| % of 52W HighCurrent price vs 52-week peak | +84.4% | +85.2% | +82.8% | +92.1% |
| RSI (14)Momentum oscillator 0–100 | 41.4 | 48.2 | 46.8 | 44.2 |
| Avg Volume (50D)Average daily shares traded | 2K | 8K | 5.8M | 33.3M |
Evenly matched — XOMAP and PFE each lead in 1 of 2 comparable metrics.
Analyst Outlook
PFE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: XOMAP as "Buy", PRTC as "Buy", ABBV as "Buy", PFE as "Hold". Consensus price targets imply 235.9% upside for PRTC (target: $57) vs 3.0% for PFE (target: $27). For income investors, PFE offers the higher dividend yield at 6.49% vs XOMAP's 1.20%.
| Metric | XOMAPXOMA Corporation | PRTCPureTech Health p… | ABBVAbbVie Inc. | PFEPfizer Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | — | $57.00 | $256.64 | $27.27 |
| # AnalystsCovering analysts | 9 | 2 | 41 | 39 |
| Dividend YieldAnnual dividend ÷ price | +1.2% | — | +3.2% | +6.5% |
| Dividend StreakConsecutive years of raises | 0 | 1 | 13 | 15 |
| Dividend / ShareAnnual DPS | $0.30 | — | $6.57 | $1.72 |
| Buyback YieldShare repurchases ÷ mkt cap | +5.2% | +5.0% | +0.3% | 0.0% |
PFE leads this category, winning 2 of 2 comparable metrics.
Key Takeaway
PFE leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). ABBV leads in 1 (Total Returns). 3 tied.
Best OverallPfizer Inc. (PFE)Leads 2 of 6 categories
Loading custom metrics...
XOMAP vs PRTC vs ABBV vs PFE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is XOMAP or PRTC or ABBV or PFE a better buy right now?
For growth investors, XOMA Corporation (XOMAP) is the stronger pick with 83.
1% revenue growth year-over-year, versus -3. 5% for PureTech Health plc (PRTC). XOMA Corporation (XOMAP) offers the better valuation at 17. 3x trailing P/E (22. 5x forward), making it the more compelling value choice. Analysts rate XOMA Corporation (XOMAP) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — XOMAP or PRTC or ABBV or PFE?
On trailing P/E, XOMA Corporation (XOMAP) is the cheapest at 17.
3x versus AbbVie Inc. at 85. 5x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — XOMAP or PRTC or ABBV or PFE?
Over the past 5 years, AbbVie Inc.
(ABBV) delivered a total return of +101. 3%, compared to -70. 1% for PureTech Health plc (PRTC). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus PRTC's -55. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — XOMAP or PRTC or ABBV or PFE?
By beta (market sensitivity over 5 years), XOMA Corporation (XOMAP) is the lower-risk stock at 0.
03β versus Pfizer Inc. 's 0. 54β — meaning PFE is approximately 1513% more volatile than XOMAP relative to the S&P 500. On balance sheet safety, PureTech Health plc (PRTC) carries a lower debt/equity ratio of 6% versus 127% for XOMA Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — XOMAP or PRTC or ABBV or PFE?
By revenue growth (latest reported year), XOMA Corporation (XOMAP) is pulling ahead at 83.
1% versus -3. 5% for PureTech Health plc (PRTC). On earnings-per-share growth, the picture is similar: XOMA Corporation grew EPS 188. 5% year-over-year, compared to -24. 0% for PureTech Health plc. Over a 3-year CAGR, XOMAP leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — XOMAP or PRTC or ABBV or PFE?
XOMA Corporation (XOMAP) is the more profitable company, earning 60.
8% net margin versus -23. 6% for PureTech Health plc — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -21. 1% for PRTC. At the gross margin level — before operating expenses — PRTC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is XOMAP or PRTC or ABBV or PFE more undervalued right now?
On forward earnings alone, Pfizer Inc.
(PFE) trades at 8. 9x forward P/E versus 22. 5x for XOMA Corporation — 13. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRTC: 235. 9% to $57. 00.
08Which pays a better dividend — XOMAP or PRTC or ABBV or PFE?
In this comparison, PFE (6.
5% yield), ABBV (3. 2% yield), XOMAP (1. 2% yield) pay a dividend. PRTC does not pay a meaningful dividend and should not be held primarily for income.
09Is XOMAP or PRTC or ABBV or PFE better for a retirement portfolio?
For long-horizon retirement investors, XOMA Corporation (XOMAP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
03), 1. 2% yield). Both have compounded well over 10 years (XOMAP: +50. 9%, PRTC: -55. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between XOMAP and PRTC and ABBV and PFE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: XOMAP is a small-cap high-growth stock; PRTC is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock; PFE is a mid-cap income-oriented stock. XOMAP, ABBV, PFE pay a dividend while PRTC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(XOMAP: 57.9% · PRTC: -30.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.